Medicilon

Medicilon, founded in 2004 and headquartered in the UK, is a leading Chinese contract research organization (CRO) focused on advancing biotechnology and pharmaceutical research. The company provides a comprehensive suite of services across the drug discovery and development lifecycle, having partnered with over 900 clients globally. Medicilon significantly contributes to human health through its dedicated R&D support, leveraging scientific excellence and integrated solutions to drive innovation in drug development within the life sciences sector.

Operational expertise at Medicilon includes medicinal chemistry, process chemistry, in vitro and in vivo drug metabolism and pharmacokinetics (DMPK), preclinical development, and bioanalytical support. Employing 1,000-5,000 professionals across its 9 locations, Medicilon maintains a robust capacity for complex research projects. Interested parties can gain insight into the team behind these achievements by visiting Meet Medicilon's team. Its global footprint is anchored by its UK headquarters, facilitating international collaborations and operational efficiency in delivering high-quality research services.

With a reported revenue of $162.4M, Medicilon demonstrates substantial market presence and demand for its specialized CRO services. Its offerings include integrated contract research, drug discovery, and development services, alongside specific capabilities like library preparation and formulation technology. Medicilon's consistent growth and client-centric approach have established its reputation as a dependable partner in the pharmaceutical R&D ecosystem. By providing critical research outsourcing and scientific support, Medicilon accelerates the path of new drugs to market, ultimately enhancing global human health.